Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

NCT03043391 | Completed Phase 1 Results DMC FDA Drug

• 1 other identifier: Pro00071228
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to confirm the safety of the selected dose and potential toxicity of oncolytic poliovirus (PV) immunotherapy with PVSRIPO for pediatric patients with recurrent WHO grade III or IV malignant glioma, but evidence for efficacy will also be sought. The primary objective is to confirm the safety of the selected dose of PVSRIPO when delivered intracerebrally by convection-enhanced delivery (CED) in children with recurrent WHO Grade III malignant glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma) or WHO Grade IV malignant glioma (glioblastoma, gliosarcoma). A secondary objective is to estimate overall survival (OS) in this population.

Conditions

Malignant Glioma; Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma; Gliosarcoma; Atypical Teratoid/Rhabdoid Tumor of Brain; Medulloblastoma; Ependymoma; Pleomorphic Xanthoastrocytoma of Brain; Embryonal Tumor of Brain

Keywords

Pediatric Malignant Glioma; PVSRIPO; Pro00071228; Eric Thompson; Darell Bigner; Oncolytic Poliovirus; Daniel Landi

Outcome Measures

Primary Outcomes (2)

• Percentage of Participants With Unacceptable Toxicity

  Percentage of participants with unacceptable toxicity during the 14-day period post-PVSRIPO treatment

  14 days after treatment with PVSRIPO

• Percentage of Participants Requiring Low-dose Bevacizumab or Steroid

  The percentage of participants requiring low-dose bevcizumab or steroid due to an inflammatory reaction secondary to an immune response to lerapolturev treatment

  1 year

Secondary Outcomes (1)

• Overall Survival

  up to 24 months

Study Arms (1)

Polio/Rhinovirus Recombinant (PVSRIPO)

EXPERIMENTAL

PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.

Biological: Polio/Rhinovirus Recombinant (PVSRIPO)

Interventions

Polio/Rhinovirus Recombinant (PVSRIPO) BIOLOGICAL

PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.

Polio/Rhinovirus Recombinant (PVSRIPO)

Eligibility Criteria

• Age: 12 Years - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients must have a recurrent supratentorial WHO Grade III malignant glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma) or WHO Grade IV malignant glioma, medulloblastoma, or atypical teratoid/rhabdoid tumor (ATRT) based on imaging studies with measurable disease (≥ 1 cm and ≤ 5.5 cm). The prior histopathology must be consistent with a World Health Organization (WHO) Grade III or IV malignant tumor confirmed by the study pathologist, Roger McLendon, or his designee.
• There is no standard of care treatment for children with Grade III/IV gliomas; however, patients must have received some form of definitive treatment, i.e., standard therapy with known clinical benefit, for their initial diagnosis prior to their recurrence/progression. Definitive treatment includes maximal safe resection (if possible) and radiation therapy with or without chemotherapy. (Please note that patients who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e., Gorlin's syndrome or NF1 mutation) are still eligible to participate).
• Due to the potential implications of the treatment on the developing CNS, all patients must be ≥ 12 years of age and ≤ 21 years of age at the time of entry into the study.
• The patient must have a Lansky or Karnofsky Performance Score (KPS) of ≥ 70% at the time of entry.
• Laboratory Studies:
• Platelet count ≥ 125,000 per microliter prior to biopsy. Platelets ≥ 100,000 per microliter prior to infusion;
• Prothrombin and Activated Partial Thromboplastin Times ≤ 1.2 x upper limit of normal (ULN) prior to biopsy;
• Positive serum anti-poliovirus titer ≥ 1:8 prior to biopsy;
• Creatinine ≤ 1.2 x ULN prior to biopsy;
• Total bilirubin, AST, ALT, alkaline phosphatase ≤ 2.5 x ULN prior to biopsy;
• Neutrophil count ≥ 1000 per microliter prior to biopsy;
• Hemoglobin ≥ 9 gm/dl prior to biopsy (can be transfused).
• The patient must have received a boost immunization with trivalent inactivated IPOL™ (Sanofi-Pasteur) ≥ 1 week prior to administration of the study agent.
• At the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysis.
• A signed informed consent form approved by the Duke University Institutional Review Board (IRB) will be required for patient enrollment into the study. Patients (if 18 years old) or their parent(s) or guardian(s) must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study. All children will have to provide assent to the study.

You may not qualify if:

• Pregnant or breast-feeding. Female patients of child-bearing potential or female sexual partners (who are of child-bearing potential) of male patients must use at least one of the following methods of medically acceptable contraceptives: approved hormonal contraceptives (such as birth control pills, patches, implants or infusions), an intrauterine device (IUD), or a barrier method of contraception (such as a condom or diaphragm) used ith spermicide. Because all patients are required to have a boost immunization of trivalent inactivated IPOL™, there should be no risk of transmission of a mother to her fetus after receiving intracranial PVSRIPO. As such, patients who become pregnant after receiving PVSRIPO will continue to be monitored in the same manner, i.e. per protocol, unless the assessment is contra-indicated during pregnancy. Partners who become pregnant will sign a Pregnant Partner Information Form and information regarding the pregnancy and its outcome may be collected.
• Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeon.
• Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (Tmax \> 99.5°F).
• Patients with known immunosuppressive disease or known human immunodeficiency virus infection.
• Patients with unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association Class 3 or 4) or lung (FEV1 \< 50%) disease, uncontrolled diabetes mellitus.
• Patients with allergy to human serum albumin.
• Current or history of anaphylactic reaction to gadolinium.
• A history of neurological complications due to past PV infection would imply previous virus replication in the CNS. Based on animal studies, previous exposure to poliovirus administered intracerebrally can reduce subsequent virus replication in the CNS.
• Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used:
• Patients who are less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 consecutive scans with disease progression or histopathologic confirmation of recurrent tumor.
• Patients who have received chemotherapy or bevacizumab ≤ 4 weeks \[except for nitrosourea (6 weeks) or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week)\] prior to starting the study drug unless patients have recovered from side effects of such therapy.
• Patients who have received immunotherapy ≤ 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapy.
• Patients with neoplastic lesions in the brainstem, cerebellum, spinal cord, intraventricular tumors, pituitary tumors, leptomeningeal disease, or other locations at the discretion of the treating neurosurgeon.
• Patients with a diagnosis of agammaglobulinemia, that is:
• Undetectable anti-tetanus toxoid IgG

Sponsors & Collaborators

• Istari Oncology, Inc.: lead
• Solving Kids' Cancer: collaborator
• The Andrew McDonough B+ Foundation: collaborator
• Duke University: collaborator

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

Related Publications (2)

• Barkley A, Butler E, Park C, Friedman A, Landi D, Ashley DM, Bigner D, Bernstock JD, Friedman GK, Johnston JM, Thompson EM. The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study. J Neurosurg Pediatr. 2024 Jan 12;33(4):359-366. doi: 10.3171/2023.12.PEDS23404. Print 2024 Apr 1.

  PMID: 38215438 DERIVED

• Thompson EM, Landi D, Brown MC, Friedman HS, McLendon R, Herndon JE 2nd, Buckley E, Bolognesi DP, Lipp E, Schroeder K, Becher OJ, Friedman AH, McKay Z, Walter A, Threatt S, Jaggers D, Desjardins A, Gromeier M, Bigner DD, Ashley DM. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. Lancet Child Adolesc Health. 2023 Jul;7(7):471-478. doi: 10.1016/S2352-4642(23)00031-7. Epub 2023 Mar 30.

  PMID: 37004712 DERIVED

Related Links

• The Preston Robert Tisch Brain Tumor Center at Duke
• The Preston Robert Tisch Brain Tumor Center at Duke Pediatric Program

MeSH Terms

Conditions

Glioma; Astrocytoma; Oligodendroglioma; Glioblastoma; Gliosarcoma; Medulloblastoma; Ependymoma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neuroectodermal Tumors, Primitive

Results Point of Contact

• Title: W. Garret Nichols, MD MS
• Organization: Istari Oncology

info@istarioncology.com

919-245-7662

Study Officials

• Darell Bigner, MD, PhD

  Istari Oncology, Inc.

  STUDY DIRECTOR

• Daniel Landi, MD

  Duke University

  PRINCIPAL INVESTIGATOR

• Eric Thompson, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Phase Ib study to evaluate feasibility, safety, and preliminary evidence of efficacy of the optimal adult dose in a pediatric population

Study Record Dates

• First Submitted: February 2, 2017
• First Posted: February 6, 2017
• Study Start: November 7, 2017
• Primary Completion: March 23, 2022
• Study Completion: March 23, 2022
• Last Updated: April 8, 2024
• Results First Posted: April 8, 2024

Record last verified: 2022-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)